BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 10623650)

  • 21. Estrogen receptor and progesterone receptor status in breast cancer in relation to age, histological grade, size of lesion and lymph node involvement.
    Sofi GN; Sofi JN; Nadeem R; Shiekh RY; Khan FA; Sofi AA; Bhat HA; Bhat RA
    Asian Pac J Cancer Prev; 2012; 13(10):5047-52. PubMed ID: 23244108
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
    Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
    Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events.
    Karlsson E; Sandelin K; Appelgren J; Zhou W; Jirström K; Bergh J; Wärnberg F
    Eur J Cancer; 2014 Feb; 50(3):517-24. PubMed ID: 24275214
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunohistochemical expression of hormone receptors in invasive breast carcinoma: correlation of results of H-score with pathological parameters.
    Thike AA; Chng MJ; Fook-Chong S; Tan PH
    Pathology; 2001 Feb; 33(1):21-5. PubMed ID: 11280603
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The estrogen receptor negative-progesterone receptor positive breast carcinoma is a biological entity and not a technical artifact.
    Ng CH; Pathy NB; Taib NA; Mun KS; Rhodes A; Yip CH
    Asian Pac J Cancer Prev; 2012; 13(4):1111-3. PubMed ID: 22799290
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is there a low-grade precursor pathway in breast cancer?
    King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
    Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oestrogen receptors alpha and beta differ in normal human breast and breast carcinomas.
    Shaw JA; Udokang K; Mosquera JM; Chauhan H; Jones JL; Walker RA
    J Pathol; 2002 Dec; 198(4):450-7. PubMed ID: 12434414
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Id4 messenger RNA and estrogen receptor expression: inverse correlation in human normal breast epithelium and carcinoma.
    de Candia P; Akram M; Benezra R; Brogi E
    Hum Pathol; 2006 Aug; 37(8):1032-41. PubMed ID: 16867866
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunohistochemical study of KiSS1 and KiSS1R expression in human primary breast cancer: Association with breast cancer receptor status, proliferation markers and clinicopathological features.
    Jarzabek K; Koda M; Kozlowski L; Milewski R; Wolczynski S
    Histol Histopathol; 2015 Jun; 30(6):715-23. PubMed ID: 25535062
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low Expression of Estrogen Receptor-α and Progesterone Receptor in Human Breast Cancer Tissues Is Associated With High-Grade Human Cytomegalovirus Protein Expression.
    Rahbar A; Touma J; Costa H; Davoudi B; Bukholm IR; Sauer T; Vetvik K; Geisler J; Söderberg-Naucler C
    Clin Breast Cancer; 2017 Nov; 17(7):526-535.e1. PubMed ID: 28595965
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and biological characteristics of breast cancer.
    Kocic B; Filipovic S; Petrovic B; Mijalkovic D; Rancic N; Poultsidi A
    J BUON; 2010; 15(4):660-7. PubMed ID: 21229626
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
    Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
    Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dissociated overexpression of cathepsin D and estrogen receptor alpha in preinvasive mammary tumors.
    Roger P; Daures JP; Maudelonde T; Pignodel C; Gleizes M; Chapelle J; Marty-Double C; Baldet P; Mares P; Laffargue F; Rochefort H
    Hum Pathol; 2000 May; 31(5):593-600. PubMed ID: 10836299
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Immunohistochemical investigation of steroid hormones (ER, PR) in breast cancer].
    Mchedlishvili MIu; Gabunia UA; Makharoblidze ER; Burnadze KT; Piradashvili DZ
    Georgian Med News; 2005 Feb; (119):65-7. PubMed ID: 15834186
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of ERalpha and ERbeta in lobular carcinoma in situ.
    Middleton LP; Perkins GH; Tucker SL; Sahin AA; Singletary SE
    Histopathology; 2007 Jun; 50(7):875-80. PubMed ID: 17543077
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of estrogen receptor beta in the breast carcinoma of BRCA1 mutation carriers.
    Litwiniuk MM; Roznowski K; Filas V; Godlewski DD; Stawicka M; Kaleta R; Breborowicz J
    BMC Cancer; 2008 Apr; 8():100. PubMed ID: 18405391
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya.
    Sayed S; Moloo Z; Wasike R; Bird P; Oigara R; Govender D; Kibera J; Carrara H; Saleh M
    Breast; 2014 Oct; 23(5):591-6. PubMed ID: 25012047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy.
    Petruolo OA; Pilewskie M; Patil S; Barrio AV; Stempel M; Wen HY; Morrow M
    Ann Surg Oncol; 2017 Sep; 24(9):2556-2562. PubMed ID: 28560596
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hormone receptors and HER2 expression in primary breast carcinoma and corresponding lymph node metastasis: do we need both?
    Raica M; Cîmpean AM; Ceausu RA; Fulga V; Nica C; Rudico L; Saptefrati L
    Anticancer Res; 2014 Mar; 34(3):1435-40. PubMed ID: 24596391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.